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Abstract
There is a real medical need of new diagnostic tools for the early recognition of invasive
Candida infections. We exploited a rather simple and rapid redox methodology to construct
a bispecific monoclonal antibody (bsmAb) that combines a monoclonal antibody (mAb)
directed against 1,3-β-D-glucan, a well-known, pan-fungal diagnostic biomarker, with a
mAb recognizing MP65, a major immunogenic mannoprotein secreted by C.albicans and
other Candida species. The bsmAb (MP65/bglu mAb) was successfully produced and puri-
fied at high yields and proved to bind and reveal simultaneously, with high sensitivity, the β-
glucan and MP65 antigens in both purified and native forms. The MP65/bglu mAb is the first
bispecific antibody generated against a fungal microorganism and may prove useful for the
concurrent detection of different and clinically significant Candida biomarkers in patient
sera.
Introduction
Invasive fungal infections caused by C. albicans and other Candida species are a major cause of
morbidity and mortality in hospitalized patients worldwide [1,2]. Despite the recent develop-
ment and clinical availability of antifungal drugs of high efficacy and reduced toxicity, these
infections remain difficult to control and their associated mortality rates are still unacceptably
high, approaching 40–50% in some cases. This is further burdened by the high cost of treat-
ment [1,2].
A main obstacle to an efficient clinical management of invasive candidiasis is the lack of
diagnostic methodologies allowing the early detection and treatment of the disease [1–5]. Cul-
ture-based diagnostics typically are too insensitive and time-consuming. A number of noncul-
tural assays, mostly based on the detection of fungal biomarkers in patient circulation, are
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making their way into the medical setting or are currently under investigation, but none have
yet proved sufficiently sensitive and specific to detect the disease at a time when fungal burden
is still relatively low and more responsive to antifungal therapy.
Several studies on the impact of treatment delays due to the time required for diagnosis
show that patient mortality and hospitalization costs increase significantly for each day without
anti-fungal therapy [3–5]. Clinicians and microbiologists agree that reliable tools for the early
recognition of the fungal infection are a strong medical need [2], either as novel strategies for
enhancing the sensitivity and specificity of current diagnostic methods or as new diagnostic
assays.
Monoclonal antibodies (mAbs) are the gold standard for early detection of diagnostically
relevant antigens. Highly specific and easily standardized, mAbs can reveal just picograms per
milliliter of the specific target. The possibility of combining two pre-existing mAbs into one
bispecific antibody (bsmAb)—a dual-Fab molecule recognizing both ligands of the mAbs of
origin—has long been known [6–10]. To date, bsmAbs have been mostly investigated as candi-
date dual targeting therapeutics for treatment of cancer or inflammatory diseases; the potential
of these reagents in the diagnosis of infectious diseases has remained almost unexplored
[11,12].
The working hypothesis of this study is that the development of bsmAbs for the simulta-
neous detection of two different and significant Candida biomarkers would make it possible to
design highly specific and sensitive assays for use in diagnosing invasive Candida infections.
Our investigation exploited bsmAb technology to combine an anti-laminarin mAb, recogniz-
ing 1,3-β-D- and 1,6-β-D-glucan sequences, with a mAb directed against MP65, an immuno-
dominant mannoprotein of C. albicans [13–16].
Materials and Methods
MAb Production and Purification
MAb 2G8, an anti-laminarin mouse IgG2b [13,14], and 4C8, a murine IgG1 recognizing the
protein moiety of the MP65 mannoprotein of C. albicans [15,16] were produced from culture
supernatants of respective hybridoma cell lines. These were concentrated using a QuixStand
benchtop system (GE Healthcare, Milano, Italy) equipped with a 30-kDa cutoff membrane and
purified by high performance liquid chromatography (HPLC) on a rProtA MabSelect Sure™
column (GE Healthcare). To this aim, the concentrated supernatants were added with 112.6 g/l
glycine, 175 g/l NaCl, and 3 g/l NaOH to achieve a pH of 8.9 and loaded onto the column at a
2 ml min−1 flow rate. Bound Igs were eluted with 3 column volumes of 0.1 M sodium citrate
buffer, pH 5.8 (mAb 4C8) or pH 3.5 (mAb 2G8) and concentrated/diafiltrated against 10 mM
sodium phosphate buffer, pH 6.7 using a Centricon Plus-80, 30-kDa MWCO, concentrator
(Millipore, Milano, Italy) [17]. The samples were then processed by preparative chromatogra-
phy on a Hydroxyapatite (HA) column (Bio-Rad, Milano, Italy) and eluted with a 110 min-lin-
ear gradient from 10 to 400 mM sodium phosphate buffer, pH 6.7, at a flow rate of 2 ml min−1.
The pooled HA peak fractions containing the mAbs were concentrated and extensively dia-
lyzed against phosphate-buffered saline (PBS), pH 7.2, using a C80 Centricon Plus (Millipore),
and finally filtered through a 0.22-μm disposable hydrophilic Posidyne membrane syringe filter
(Pall, Ann Arbor, MI, 25-mm diameter).
The IgG concentration was monitored and measured by absorbance at 280 nm throughout
the entire process. Evaluation of retention times, peak heights and relative peak areas were
made using the Gold Beckman software [18].
A Bispecific Antibody to Candida Species
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Redox Methodology
The 2G8/4C8 bsmAb was prepared by adapting the redox method described by Carling et al.
[19]. To reduce the parental mAbs to monovalent antibody (mvAb), 2-mercaptoethanesulfonic
acid sodium salt (Sigma-Aldrich, USA) was diluted in H2O and added to 1 mg of mAb 2G8 or
to 1 mg of mAb 4C8, both diluted in PBS, pH 7.2, at the final concentration of 10 mM (mAb
2G8) or 30 mM (mAb 4C8). The samples were incubated at 37°C for 25 min. Re-association of
mvAbs into bsmAbs was induced by mixing the reduced 2G8 and 4C8 mAbs (1:1 ratio), fol-
lowed by oxidation through dialysis against 3 buffer exchanges of PBS, pH 7.2 (24 h at 4°C).
Purification and Characterization of the bsmAb
The bsmAb was purified by a two-step chromatography separation onto an HA column, after
careful selection of appropriate fractionation gradient. Purification was performed at a flow-
rate of 2 ml/min using 10 mM phosphate buffer, pH 6.7 as buffer A and 400 mM phosphate
buffer, pH 6.7 as buffer B [18]. The eluted fractions from the first HA column were dialyzed
against PBS and subsequently re-purified in a second HA column to isolate the peak containing
the 2G8/4C8 bsmAb. The peak fractions corresponding to the active bsmAb were pooled, dia-
lysed against sterile PBS and stored at -20°C.
SDS-PAGE analysis of purified bsmAb and parental mAbs was performed onto 10% poly-
acrylamide gels under reducing and non-reducing conditions, according to standard tech-
niques [20]. Isotype class and subclass were analyzed by a standard immunodiffusion test [21],
using goat anti-mouse IgG1, IgG2a, IgG2b, IgG3 and IgM antibodies, respectively (SouthernBio-
tech, Birmingham, AL).
2D-IEF analysis was performed using ready-made immobilized pH gradient (IPG) strips
(7-cm IPG strips, pH 3–10). Each sample (250 μg of protein for preparative gels) was applied
onto an IPG strip by in-gel rehydration for 20 h, with the addition of dithiothreitol (DTT) and
Ampholine pH 3–10. IEF was carried out in a Protean IEF cell apparatus (Bio-Rad, Segrate,
Italy). Focusing was performed at 18°C with a limit of 50 mA per strip. Subsequently, IPG
strips were equilibrated for 15 min in 6 M urea, 2% SDS, 0.05 M Tris-HCl pH 8.8, 20% glycerol,
1% DTT buffer and for 12 min in 6 M urea, 2% SDS, 0.05 M Tris-HCl pH 8.8, 20% glycerol,
2.5% iodoacetamide buffer. For the second dimension, strips were run into 10% acrylamide
gels in a Mini Protean system (Bio-Rad). Gels were stained with colloidal Coomassie blue G-
250. Image analysis was performed using the PD-Quest software (version 7.2, Bio-Rad),
according to the manufacturer’s instructions. Normalization of each individual spot was per-
formed according to the total quantity of the valid spots in each gel, after subtraction of the
background values. The spot volume was used as the analysis parameter to quantify protein
expression.
Antigens
Laminarin was purchased from Sigma-Aldrich, USA. Recombinant MP65p, expressed in E.coli
on the basis of the published sequence [22] and purified from bacterial culture supernatants,
was produced by GeneScript, Piscataway, NJ. Concentrated and dyalized culture supernatants
containing the antigenic material secreted by plastic-adherent, hyphal form-growing C.albicans
(SAM) were obtained as described previously [13].
Biotin labelling of laminarin was performed essentially as described byWang et al. [23].
Beta-1,6-linked, branch residues of the polysaccharide were oxidized by sodiummetaperiodate
(Sigma-Aldrich) and newly formed aldheyde groups were reacted with ethylenediamine (Sigma-
Aldrich). Resulting Schiff base was stabilized by reduction with sodium borohydride (Sigma-
Aldrich) and the aminated polysaccharide was finally reacted with theN-hydroxysuccinimide
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ester of biotin (BNHS, Sigma-Aldrich) and purified by precipitation with 95%, v/v ethanol in
the cold and repeated washings. MP65p was biotinylated by direct reaction with BNHS in 1M
carbonate buffer, pH 8.3 (ratio protein to BNHS, 10:1) and purified by diafiltration against PBS
buffer in a 10 kDal MWCO ultrafiltration device (Millipore, Milano, Italy).
Analytical Determinations
Polysaccharide or protein content in the preparations of purified mAbs, bsmAb, biotinylated
antigens or SAM were determined by the phenol-sulphuric acid method or by the MicroBCA
Protein assay (Bio-Rad Laboratories), respectively, as previously reported [14].
Immunoenzymatic Assays
In indirect ELISA experiments, the various antigens were diluted in 0.05 M carbonate/bicar-
bonate buffer, pH 9.6 (laminarin, 50 μg/ml; MP65p, 5.0 μg/ml; SAM, 5.0 μg/ml protein, unless
otherwise specified) and adsorbed onto polystyrene microtiter plates (MaxiSorp; NUNC).
Plates were blocked with 3% bovine serum albumin (BSA, Fraction V, Sigma-Aldrich) in PBS
and reacted with two-fold dilutions of the parental mAbs or bsmAb, followed by alkaline phos-
phatase-conjugated, anti-mouse IgG antibody (Sigma-Aldrich) and the enzyme substrate (p-
nitrophenyl phosphate disodium, Sigma-Aldrich), as previously described [13]. Absorbance
was read at 405 nm and readings from negative controls (wells non reacted with the mAbs or
reacted with an irrelevant mAb) were subtracted from all absorbance values.
In capture ELISA, MaxiSorp plates were coated with an Fc-specific, goat anti-mouse IgG
antibody (5 μg/ml in PBS, on, +4°C), washed and reacted with the bsmAb at the desired dilu-
tions in PBS (1h, 37°C). After thorough washings and blocking with 3% BSA in PBS, the plate-
bound bsmAb was reacted with different concentrations of biotinylated laminarin or MP65p
for 1h at 37°C. Wells were washed again and the amount of bound antigen was evaluated by
the addition of horse-radish peroxidase-conjugated streptavidin (Sigma-Aldrich) followed by
3,30,5,50-tetramethylbenzidine-H2O2 substrate solution (1-step Ultra-TMB ELISA, Thermo
Scientific, USA). Wells were acidified by addition of 1M H2SO4 and absorbance read at 450
nm. Negative control wells (non reacted with the bsmAb or with the biotinylated antigens)
were always run in parallel to evaluate background O.D. values.
Statistics
Linear regression analysis of bsmAb binding curves and Student’s t test were performed using
the Prism 4 software (GraphPad, USA).
Results
Parental mAbs
To develop the MP65/bglu mAb we selected two mAbs that specifically recognize two different,
disease-relevant, fungal antigens. The first (mAb 2G8) is a murine IgG2b specific for β-1,3-glu-
can, a cell wall component expressed and secreted by nearly all fungal pathogens [13,14]. The
second mAb (4C8) is a mouse IgG1 that recognizes the protein moiety of MP65 (MP65p), a
highly immunogenic mannoprotein involved in Candida cell wall maintenance and remodel-
ing [15,16,24].
The parental mAbs were massively produced in cell cultures, and supernatants underwent
all the steps for purification as described [17]. The purified mAbs maintained the purity grade
and binding efficiency shown by reference mAb preparations, as assessed by SDS-PAGE analy-
ses and ELISA testing (data not shown).
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Production of the bsmAb
The construction of the MP65/bglu mAb relied upon a rapid method based on reduction-oxi-
dation of the parental IgGs [19]. As illustrated in Fig 1, the method exploits the mild reducing
Fig 1. Schematic diagram of MP65/bglumAb generation by the redoxmethod.Modified from: Carlring
et al., PLoS One. 2011;6: e22533.
doi:10.1371/journal.pone.0148714.g001
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agent 2-mercaptoethanesulfonic acid (MESNA) to break the inter-heavy chain bonds of the
parental IgGs and to reduce them to monovalent mAbs (mvAbs). Subsequent dialysis under
oxidizing conditions provided re-associations of the mvAbs to form bsmAb molecules.
Preliminary experiments were performed to establish the optimal conditions of MESNA
treatment for obtaining mvAbs from the parental 2G8 and 4C8 IgG. Different concentrations
of MESNA and different incubation times were used to reduce the purified mAbs. The compo-
sition of the resulting products was then analyzed by non-reducing SDS-PAGE. The optimal
reduction of the 2G8 mAb was obtained at a MESNA concentrations of 10 mM, as indicated by
the presence of a sharp mvAb band at ~75 kDa in the electrophoretic profile of the final reac-
tion mixture (Fig 2A). Instead, 30 mMMESNA yielded the highest amount of mvAb frag-
ments, with a molecular weight of ~85 kDa, from the 4C8 mAb (Fig 2B). Both reduced mAb
preparations showed only a faint band attributable to the intact mAb, confirming their high
susceptibility to reduction at the conditions adopted (Fig 2A and 2B). MESNA reduction also
led to the release of small amounts of free heavy and light mAb chains, which were almost
totally removed by subsequent dialysis (Fig 2). These experiments defined the optimal incuba-
tion conditions for MESNA treatment were exposure of IgG at 37°C for 25 min (data not
shown).
Reassembling of mvAbs into bsmAbs was initiated by mixing equal amounts of reduced
2G8 and 4C8 mvAbs, followed by oxidation through dialysis against PBS [19]. SDS-PAGE
analysis of the mvAbs mixture after the dialysis step showed an almost complete re-assemblage
of the immunoglobulins, as shown by the presence of a major band at 150 kDa (Fig 2C).
MvAbs re-associate randomly during the oxidizing reaction, hence the 150 kDa product repre-
sented a mixture of re-assembled original mAbs and newly formed bsmAb molecules (Fig 1).
MP65/bglu mAb Purification
The bsmAb was composed by two different and monovalent IgG moieties (mvIgG), each of
which corresponded to one half of the parental IgGs (Fig 1). The resulting total net charge of
this molecule (mvIgG1 x mvIgG2b) was thus different from that of the parental mAbs (mvIgG1
x mvIgG1 or mvIgG2b x mvIgG2b). HPLC on hydroxyapatite (HA) led to an efficient separation
Fig 2. Tuning redoxmethodology for MP65/bglumAb construction. Panels A and B show the efficiency of different MESNA concentrations (0 to 50 mM,
as indicated) in splitting mAb 2G8 (A) or mAb 4C8 (B) into mvAb fragments, as evaluated by their SDS-PAGE profiles under non-reducing conditions. The
arrows indicate the presence of the whole mAb (1), mvAb (2), heavy chain (3), and light chain (4). Panel C shows a non-reducing SDS-PAGE analysis of the
2G8/4C8mvAb mixture after oxidation by dialysis, demonstrating the re-association of mvAb fragments into whole Ig molecules. MW =molecular weight
standards.
doi:10.1371/journal.pone.0148714.g002
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of the MP65/bglu mAb and the re-assembled 2G8 or 4C8 mAbs according to their individual
charges [25]. Successful purification of the bsmAb, however, critically required the choice of
gradients of appropriate ionic strength for the chromatographic separation, as to obtain signifi-
cant differences in the retention times of the bsmAb and the parental mAbs. Gradients were
selected by careful evaluation of the retention times of the parental mAbs in different condi-
tions. As shown in Fig 3, HA chromatography allowed the purification of a definite peak attrib-
utable to the bsmAb, distinct from those originated by the parental 2G8 and 4C8 mAbs.
To verify the identity of the MP65/bglu mAb peak, fractions corresponding to the ascending
and descending part were collected separately and referred to as 5/A (ascending peak) and 5/B
(descending peak) fraction (Fig 3C).
Classical Ouchterlony tests (Fig 4A) clearly showed that the two fractions were recognized
by both anti-IgG1 and anti-IgG2b antibodies. Precipitin lines were of similar intensity, confirm-
ing that 5/A and 5/B were both a combined IgG1 x IgG2b complex.
Fig 3. Purification of the MP65/bglumAb by HA-ion-exchange chromatography. Elution profiles of the 2G8 and 4C8mAbs (Panel A), the 2G8 x 4C8
bsmAb (Panel B) and merge of all three profiles (Panel C); in C, the bsmAb peak is indicated by the dotted, red line. Chromatographic separation was
performed on a 50 x 25 mm I.D. HA column at a flow rate of 2 ml/min. A 110 min linear gradient from 10 to 400 mM phosphate (dotted black line) was used. In
B, dotted line inside of the bsmAb elution peak shows its separation into the two fractions 5/A and 5/B.
doi:10.1371/journal.pone.0148714.g003
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Fig 4. Characterization of the 5/A and 5/B bsmAb fractions. Panel A. Reactivity of 5/A and 5/B in the Ouchterlony double immunodiffusion assay.
Central well 1 was loaded with fraction 5/A and central well 4 with fraction 5/B. Side well 2 contained a goat, anti-mouse IgG1 mAb and side well 3 a goat anti-
mouse IgG2b mAb. Panel B. 2D-IEF analysis of the bsmAb fractions in comparison with the 2G8 and 4C8 parental mAbs. IEF separation was
performed as described in Materials and Methods. Image analysis of the stained gels was performed using the PD-Quest software. Circle of the same color
indicate corresponding protein spots in different mAb samples. Panel C. Binding of the bsmAb fractions to β-glucan andMP65p. Laminarin or MP65p
A Bispecific Antibody to Candida Species
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2D-IEF analysis showed that the fingerprints of the two fractions were almost identical in
quantity and quality and substantially corresponded to the combination of the individual fin-
gerprints exhibited by the parental mAbs (Fig 4B).
Finally, the fractions were assayed for reactivity with laminarin, a standard β-1,3 glucan
polysaccharide, or with recombinant MP65p, used as solid-phase antigens in ELISA. The
parental 2G8 and 4C8 mAbs were tested at the same concentrations as reactivity reference
standards. The results demonstrated that both 5/A and 5/B were able to recognize plastic-
adsorbed laminarin or MP65p, in a dose-dependent fashion (Fig 4C). Comparison of the bind-
ing efficiency of the two fractions, as exemplified by the final assay outputs produced (O.D. 405
nm), indicated an almost identical reaction patterns with MP65p and a slightly more efficiency
in binding laminarin by 5/B (Fig 3C). However, the reactivity of the bsmAb fractions was com-
parable to that exhibited by the parental mAbs, at least at the highest doses.
Based on these results, subsequent experiments were performed using the entire bsmAb
peak.
Validation of the bsmAb
Definitive validity of the construct was investigated by testing its ability to bind simultaneously
and independently the epitopes recognized by the parental mAbs and by evaluating whether,
and at what level of sensitivity, the MP65/bglu mAb was able to capture the free target antigens
in solution. This was critical to envision the potential of the bsmAb as a single, specific reagent
able to reveal as a whole both the β-glucan and MP65p diagnostic antigens in the sera of Can-
dida infected patients.
First, the MP65/bglu mAb was assayed in indirect ELISA experiments against a combina-
tion of the antigens recognized by the parental mAbs as the plastic-adsorbed target (Fig 5). The
combination was either a mixture of laminarin and recombinant MP65p or a concentrated cul-
ture supernatant of hyphal form-growing C.albicans (SAM), a preparation that is known to
contain both the β-glucan and MP65 antigens as they are naturally expressed and secreted by
the fungus [13,16,26]. Results from these experiments showed that reaction of the bsmAb with
both the laminarin-MP65p mixture (Fig 5A) or the native fungal SAM (Fig 5B), at all doses
tested, produced final O.D. readings approximately equivalent, if not slightly higher, to the
sum of those produced by each parental mAb against its respective antigen. This clearly indi-
cated that bsmAb could indeed bind the β-glucan and Mp65 antigens simultaneously and inde-
pendently, as expected, with no loss of functional affinity with respect to the mAbs of origin
and even in the form they are natively produced by fungal cells.
In all conditions tested, O.D. readings generated by the bsmAb were significantly higher
(P<0.01, Student’s t test) than those generated by the mAb 2G8. Differences between readouts
produced by the bsmAb and the mAb 4C8 were always statistically significant (P<0.05, Stu-
dent t test) except when the two mAbs were compared at the concentration of 1μg/ml against
the laminarin-MP65p mixture.
Following these experiments, we constructed ELISA assays in which the bsmAb was bound
to the plate and evaluated for its ability to capture and reveal biotin-labelled laminarin or
MP65p in solution. Checkerboard titration experiments showed that the bsmAb was efficient
at capturing both antigens (Fig 6A and 6B). The outputs (final O.D. readings) of the assays
adsorbed onto ELISA plates were reacted with fraction 5/A or 5/B or with the parental mAb 2G8 or 4C8, at the concentrations indicated. Binding of the Abs
was revealed by an alkaline phosphatase-conjugated, anti-mouse IgGmAb followed by p-nitrophenyl phosphate disodium as the enzyme substrate. Binding
is expressed as the mean, O.D. 405 nm readings from triplicate wells after subtraction of O.D. from the negative controls (wells with irrelevant Abs). The SD
of all triplicate determinations was always <20% and is not shown in the graph.
doi:10.1371/journal.pone.0148714.g004
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were MP65/bglu.mAb- and antigen-dose dependent. Further, a good linearity was found for
antigen dose-O.D. response curves obtained at all the different bsmAb concentrations assayed,
with r2 values always approximating 1.0 (Fig 6A and 6B). Finally, the output of the experiments
was readable at antigen concentrations as low as 50 pg/mL-1 (laminarin) or 150 pg/mL-1
(MP65p), demonstrating that the MP65/bglu mAb had a high avidity for both fungal biomark-
ers (Fig 6A and 6B). In other experiments (Fig 6C), the ELISA plate-bound MP65/bglu mAb
was also reacted in parallel with different doses of biotinylated laminarin or MP65p, separate
or mixed toghether. Similarly to what observed previously (see Fig 5), O.D. readings resulting
upon capture of the antigen mixture roughly approximated the summed values generated by
the capture of each single antigen, indicating that β-glucan and MP65p did not exert any
mutual steric hindrance or generic interference in binding to the bsmAb (Fig 6C).
Overall, these results suggested that the MP65/bglu mAb was very efficient and sensitive for
the synchronous capture and revelation of the two fungal biomarkers.
Discussion
Despite the huge potentialities of bsmAbs for the detection and treatment of cancer and other
human diseases, only few examples of bsmAb devised for anti-bacterial or anti-fungal therapy
are reported in current literature [27–32]. BsmAbs proposed for the diagnosis of human micro-
bial infections are even fewer, and were all constructed to bind in combination a microbial anti-
gen and various types of reporter molecule, in order to improve antigen recognition specificity
in different immunoassays [33–35].
We describe here the development and characterization of a novel, anti-Candida bsmAb
(MP65/bglu mAb) designed for the dual-detection of two diverse, diagnostically relevant,
Fig 5. The bsmAb is able to bind contemporaneously and independently the β-glucan and MP65p antigens. The ELISA plates were coated with a
mixture of laminarin and MP65p (20 and 5.0 μg/ml, respectively) or with a concentrated culture supernatant of C.albicans hyphae (SAM, 5.0 μg/ml protein)
containing naturally secreted β-glucan and MP65. The graph shows a comparison of mean O.D.405 nm values resulting upon reaction of the antigen
mixtures with mAb 2G8, mAb 4C8 or bsmAb 2G8X4C8, at the indicated concentrations. SD between replicates was always <20% and is not reported.
doi:10.1371/journal.pone.0148714.g005
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fungal biomarkers in patient sera. The bsmAb was constructed from two previously described
murine mAbs [13,14,16], that recognize two Candida antigens whose levels are known to
increase in patient circulation in the course of the fungal infection. One of them is the pan-fun-
gal polysaccharide β-glucan, a well-established disease biomarker that is currently assayed for
the diagnosis of infections caused by different fungi, including Candida [36]. The companion
antigen, MP65p, is a protein originally identified by us in C.albicans as the main fungal antigen
targeted by the human cellular immune responses [15,16,37]. MP65p is secreted at very high
levels, in vivo and in vitro, particularly by Candida hyphae which are the form of growth gener-
ally associated to infectious candidiasis [24,26]. Close homologues of this protein are also
expressed and secreted by most of the pathogenic Candida species, such as C. guilliermondii, C.
glabrata, C. parapsilosis and C. tropicalis [22]. Building upon our previous work, other authors
have more recently proposed MP65p as a valid marker of Candida infection, although it is not
yet used in clinical diagnostics [24].
Fig 6. Antigen capture by the MP65/bglumAb. Panel A and B. Dose-response, β-glucan and MP65p capture curves. An Fc-specific, goat anti mouse
IgG coating was used for the oriented binding of the bsmAb, at various concentrations, to the ELISA plates. Plate-bound bsmAb was then reacted with
different doses of biotinylated laminarin (Panel A) or MP65p (Panel B). The amount of captured antigens was revealed by the addition of peroxidase-
conjugated streptavidin followed by the enzyme substrate. O.D. 450 nm readings are the mean from duplicate wells after subtraction of O.D. values from the
negative controls (wells with no antigen or no bsmAbs). R2 values of the resulting capture curves were calculated by linear regression analysis. Panel C.
Dual antigen capture by the bsmAb. The ELISA plate-bound bsmAb (0.2 μgml) was reacted in comparison with different doses of biotinylated laminarin or
biotinylated MP65p or with a mixture containing both biotynilated laminarin and MP65p. The ELISA assay was performed as described above for data in
Panels A and B.
doi:10.1371/journal.pone.0148714.g006
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Traditional methods of producing bsmAb rely on immunoglobulin G (IgG) heterocross-
linking or the production of hybrid hybridomas [25]. Alternative methods, such as Fc-engi-
neering [38], chemical redox [19,39] or both [40–42], have been under development in the last
few years. Hybrid hybridomas and engineering are highly sensitive as well as consistent, but
they are time consuming and expensive. To construct the MP65/bglu mAb, we applied a man-
ageable chemical redox methodology that has proven successful and time-saving for obtaining
different types of bsmAbs, and that is particularly suitable for the production of bsmAb
reagents for use in early pilot studies. Our results show that by coupling the redox strategy with
HA purification, the production of bsmAbs from homospecific immunoglobulins of different
isotypes is both simple and efficient. We were able to produce and purify the bsmAb with yields
of up to 50%, which is twice that previously reported [19].
The bsmAb generated could simultaneously bind with high affinity the β-glucan and
MP65p antigens. Indeed, both ELISA experiments with plastic-adsorbed antigen mixtures and
ELISA dual-capture assays showed that the MP65/bglu mAb produced readout values that
were essentially the sum of those individually produced by the two mAbs of origin. These
results also indicate that, at least in our assay conditions, the overall avidity of the two bsmAb
binding arms is preserved, if not increased, with respect to the two entire parental mAbs sug-
gesting that assemblage of the 2G8 and 4C8 mAbs could enhance the affinity and/or avidity of
one or both antigen binding sites in the resulting bispecific Ig. This might be caused by the
structural diversity of the constant regions of the MP65/bglu mAb, that is a combined
IgG1xIgG2 molecule, unlike the IgG1 and IgG2 mAbs of origin. In fact, it is well known that
variations of the constant regions can significantly impact the affinity and even the fine speci-
ficity of Abs with identical antigen binding sites [43,44]. Moreover, an altered avidity of
bsmAbs as compared to parental mAbs has been reported by several authors [45–47].
ELISA capture curves revealed a high efficiency of the MP65/bglu mAb in detecting the fun-
gal antigens. In particular, the sensitivity of the bsmAb effectively detected either β-glucan or
MP65p at very low concentrations, such as those that are present and considered diagnostically
significant in Candida-infected patients [24,36].
The standard β-glucan (laminarin) and the recombinant MP65p used in this investigation
are mock antigens that express the epitopes recognized by the bmAb parental Igs but are
structurally different from the native fungal antigens. Fungal β-glucan, for instance, is much
more extensively branched than laminarin, while MP65p is released by fungal cells in a heavily
mannosylated form. Therefore, the ability to recognize naturally released β-glucan and
MP65p in hyphal secretion, a material that mimics the antigenic secretion produced by the
infecting fungus in vivo, is another important and diagnostically relevant feature of our
MP65/bglu mAb.
Early serological diagnosis of invasive candidiasis remains a real challenge. Specific
approaches already attempted in this field have included the detection of fungal DNA using
PCR-based methods or the analysis of circulating fungal biomarkers in patient sera [36]. PCR
methodologies mostly proved difficult to standardize and are as yet experimental. Instead,
commercial assays of 1,3-β-D-glucan or α-1,2-D-/α-1,6-D-mannan, two cell wall polysaccha-
rides which increase in serum levels in the course of infection, are now commonly used in clin-
ics [36]. These, however, have multiple drawbacks in terms of sensitivity and specificity and
sometimes must be ran in combination to consolidate their diagnostic significance [36].
We consider that the MP65/bglu mAb produced in this work has the potential to contribute
to the development of new, “two-in-one” biomarker assays for an earlier and more reliable
diagnosis of candidiasis and to open the way to the use of bsmAbs as novel and potent reagents
for the sensitive detection of infection biomarkers.
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